Kailera Therapeutics, Inc.
NASDAQ: KLRA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ronald C. Renaud Jr.
- Employees
- 145
- Headquarters
- Waltham, United States
- IPO year
- 2026
- Market cap
- $2.7B
- Website
- www.kailera.com
Loading KLRA…
Loading profile data…Frequently asked questions about KLRA
What does Kailera Therapeutics, Inc. (KLRA) do?
Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on inno...
Where does KLRA trade?
Kailera Therapeutics, Inc. (KLRA) trades on the NASDAQ Global Select.
What sector is KLRA in?
Kailera Therapeutics, Inc. (KLRA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kailera Therapeutics, Inc.?
Ronald C. Renaud Jr. is the chief executive officer of Kailera Therapeutics, Inc. (KLRA).
Where is Kailera Therapeutics, Inc. headquartered?
Kailera Therapeutics, Inc. is headquartered in United States.
Does KLRA pay a dividend?
Kailera Therapeutics, Inc. (KLRA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KLRA go public?
Kailera Therapeutics, Inc. (KLRA) completed its initial public offering in 2026.